Tenaya Therapeutics (TNYA) EBITDA Margin (2026)
Tenaya Therapeutics' EBITDA Margin was -1130.11% in Q3 2026, up 2688.81 percentage points from the prior quarter.
Powered by 
Analysis
Tenaya Therapeutics (TNYA) EBITDA Margin (2026) Analysis & Trends
On a trailing twelve-month basis, Tenaya Therapeutics' EBITDA Margin was -3259.17% through Sep 30, 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 54.65% |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 40.75% |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | - |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 42.49% |
| 10 | Tenaya Therapeutics | 90.81 Mn | 24.01 Mn | - | -1,130.11% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -1,130.11% |
| Jun 30, 2026 | -3,818.92% |
| Mar 31, 2026 | -8,134.22% |
API Access
Tenaya Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=TNYA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "TNYA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=TNYA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();